“Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium”. Cellular and Molecular Life Sciences63 (2): 144–62. (Jan 2006). doi:10.1007/s00018-005-5421-8. PMID16416260.
“Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha”. Science286 (5444): 1583–7. (Nov 1999). doi:10.1126/science.286.5444.1583. PMID10567269.
“Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP”. The American Journal of Physiology267 (5 Pt 1): C1405–13. (Nov 1994). doi:10.1152/ajpcell.1994.267.5.C1405. PMID7977701.
“Characterization of the human endothelial nitric-oxide synthase promoter”. The Journal of Biological Chemistry274 (5): 3076–93. (Jan 1999). doi:10.1074/jbc.274.5.3076. PMID9915847.
“Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression”. American Journal of Physiology. Cell Physiology291 (5): C803–16. (Nov 2006). doi:10.1152/ajpcell.00457.2005. PMID16738003.
“Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis”. Trends in Cell Biology4 (7): 231–5. (Jul 1994). doi:10.1016/0962-8924(94)90114-7. PMID14731661.
“Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity”. The Journal of Biological Chemistry272 (30): 18522–5. (Jul 1997). doi:10.1074/jbc.272.30.18522. PMID9228013.
“A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins”. Basic & Clinical Pharmacology & Toxicology106 (5): 357–61. (May 2010). doi:10.1111/j.1742-7843.2010.00551.x. PMID20210789.
“T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm”. Circulation99 (22): 2864–70. (Jun 1999). doi:10.1161/01.cir.99.22.2864. PMID10359729.
“The polymorphism for endothelial nitric oxide synthase gene, the level of nitric oxide and the risk for pre-eclampsia: a meta-analysis”. Gene519 (1): 187–93. (Apr 2013). doi:10.1016/j.gene.2013.01.004. PMID23375994.
“Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus”. Genetic Testing and Molecular Biomarkers16 (6): 574–9. (Jun 2012). doi:10.1089/gtmb.2011.0218. PMID22313046.
“The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy”. Nitric Oxide13 (1): 88–92. (Aug 2005). doi:10.1016/j.niox.2005.04.004. PMID15890549.
“Association of endothelial nitric oxide synthase gene polymorphisms (894G/T, -786T/C, G10T) and clinical findings in patients with migraine”. Neuromolecular Medicine16 (3): 587–93. (Sep 2014). doi:10.1007/s12017-014-8311-0. PMID24845269.
“Association of the T-786C, G894T and 4a/4b polymorphisms of the endothelial nitric oxide synthase gene with vasculogenic erectile dysfunction in Iranian subjects”. BJU International107 (12): 1994–2001. (Jun 2011). doi:10.1111/j.1464-410X.2010.09755.x. PMID20955262.
“Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear”. FASEB Journal21 (11): 2655–63. (Sep 2007). doi:10.1096/fj.06-7088com. PMID17449720.
“The association between endothelial nitric oxide synthase gene G894T polymorphism and hypertension in Han Chinese: a case-control study and an updated meta-analysis”. Annals of Human Biology42 (2): 184–94. (Mar 2015). doi:10.3109/03014460.2014.911958. PMID24846690.
“Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias”. Journal of Hypertension25 (9): 1763–74. (Sep 2007). doi:10.1097/HJH.0b013e3281de740d. PMID17762636.
“Association of endothelial nitric oxide synthase gene polymorphisms with type 2 diabetes mellitus: a meta-analysis”. Endocrine Journal60 (7): 893–901. (2013). doi:10.1507/endocrj.ej12-0463. PMID23563728.
“The association of eNOS G894T polymorphism with metabolic syndrome and erectile dysfunction”. The Journal of Sexual Medicine9 (3): 837–43. (Mar 2012). doi:10.1111/j.1743-6109.2011.02588.x. PMID22304542.
“eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes”. European Journal of Clinical Investigation42 (7): 729–37. (Jul 2012). doi:10.1111/j.1365-2362.2011.02638.x. PMID22224829.
“eNOS haplotype associated with hypertension in obese children and adolescents”. International Journal of Obesity35 (3): 387–92. (Mar 2011). doi:10.1038/ijo.2010.146. PMID20661250.
“Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus”. Atherosclerosis189 (1): 241–6. (Nov 2006). doi:10.1016/j.atherosclerosis.2005.12.011. PMID16427644.
“Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy”. Journal of Hypertension24 (12): 2393–7. (Dec 2006). doi:10.1097/01.hjh.0000251899.47626.4f. PMID17082721.
“Endothelial nitric oxide synthase haplotypes associated with hypertension do not predispose to cardiac hypertrophy”. DNA and Cell Biology29 (4): 171–6. (Apr 2010). doi:10.1089/dna.2009.0955. PMID20070154.
“Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia”. Molecular Human Reproduction16 (7): 506–10. (Jul 2010). doi:10.1093/molehr/gaq030. PMID20457799.
“Endothelial nitric oxide synthase genotype and haplotype are not associated with diabetic retinopathy in diabetes type 2 patients”. Nitric Oxide15 (4): 417–22. (Dec 2006). doi:10.1016/j.niox.2006.02.002. PMID16581274.
“eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril”. European Journal of Clinical Pharmacology69 (2): 167–77. (Feb 2013). doi:10.1007/s00228-012-1326-2. PMID22706620.
“Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction”. The Pharmacogenomics Journal13 (2): 189–96. (Apr 2013). doi:10.1038/tpj.2011.49. PMID22064666.
“Pharmacogenetics of erectile dysfunction: navigating into uncharted waters”. Pharmacogenomics15 (11): 1519–38. (Aug 2014). doi:10.2217/pgs.14.110. PMID25303302.
“Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium”. Cellular and Molecular Life Sciences63 (2): 144–62. (Jan 2006). doi:10.1007/s00018-005-5421-8. PMID16416260.
“Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha”. Science286 (5444): 1583–7. (Nov 1999). doi:10.1126/science.286.5444.1583. PMID10567269.
“Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP”. The American Journal of Physiology267 (5 Pt 1): C1405–13. (Nov 1994). doi:10.1152/ajpcell.1994.267.5.C1405. PMID7977701.
“New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases”. Clinical Chemistry45 (1): 7–17. (Jan 1999). PMID9895331.
“Ferritin: a cytoprotective antioxidant strategem of endothelium”. The Journal of Biological Chemistry267 (25): 18148–53. (Sep 1992). PMID1517245.
“Characterization of the human endothelial nitric-oxide synthase promoter”. The Journal of Biological Chemistry274 (5): 3076–93. (Jan 1999). doi:10.1074/jbc.274.5.3076. PMID9915847.
“Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression”. American Journal of Physiology. Cell Physiology291 (5): C803–16. (Nov 2006). doi:10.1152/ajpcell.00457.2005. PMID16738003.
“Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis”. Trends in Cell Biology4 (7): 231–5. (Jul 1994). doi:10.1016/0962-8924(94)90114-7. PMID14731661.
“Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity”. The Journal of Biological Chemistry272 (30): 18522–5. (Jul 1997). doi:10.1074/jbc.272.30.18522. PMID9228013.
“A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins”. Basic & Clinical Pharmacology & Toxicology106 (5): 357–61. (May 2010). doi:10.1111/j.1742-7843.2010.00551.x. PMID20210789.
“T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm”. Circulation99 (22): 2864–70. (Jun 1999). doi:10.1161/01.cir.99.22.2864. PMID10359729.
“The polymorphism for endothelial nitric oxide synthase gene, the level of nitric oxide and the risk for pre-eclampsia: a meta-analysis”. Gene519 (1): 187–93. (Apr 2013). doi:10.1016/j.gene.2013.01.004. PMID23375994.
“Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus”. Genetic Testing and Molecular Biomarkers16 (6): 574–9. (Jun 2012). doi:10.1089/gtmb.2011.0218. PMID22313046.
“The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy”. Nitric Oxide13 (1): 88–92. (Aug 2005). doi:10.1016/j.niox.2005.04.004. PMID15890549.
“Association of endothelial nitric oxide synthase gene polymorphisms (894G/T, -786T/C, G10T) and clinical findings in patients with migraine”. Neuromolecular Medicine16 (3): 587–93. (Sep 2014). doi:10.1007/s12017-014-8311-0. PMID24845269.
“Association of the T-786C, G894T and 4a/4b polymorphisms of the endothelial nitric oxide synthase gene with vasculogenic erectile dysfunction in Iranian subjects”. BJU International107 (12): 1994–2001. (Jun 2011). doi:10.1111/j.1464-410X.2010.09755.x. PMID20955262.
“Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear”. FASEB Journal21 (11): 2655–63. (Sep 2007). doi:10.1096/fj.06-7088com. PMID17449720.
“The association between endothelial nitric oxide synthase gene G894T polymorphism and hypertension in Han Chinese: a case-control study and an updated meta-analysis”. Annals of Human Biology42 (2): 184–94. (Mar 2015). doi:10.3109/03014460.2014.911958. PMID24846690.
“Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias”. Journal of Hypertension25 (9): 1763–74. (Sep 2007). doi:10.1097/HJH.0b013e3281de740d. PMID17762636.
“Association of endothelial nitric oxide synthase gene polymorphisms with type 2 diabetes mellitus: a meta-analysis”. Endocrine Journal60 (7): 893–901. (2013). doi:10.1507/endocrj.ej12-0463. PMID23563728.
“The association of eNOS G894T polymorphism with metabolic syndrome and erectile dysfunction”. The Journal of Sexual Medicine9 (3): 837–43. (Mar 2012). doi:10.1111/j.1743-6109.2011.02588.x. PMID22304542.
“eNOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes”. European Journal of Clinical Investigation42 (7): 729–37. (Jul 2012). doi:10.1111/j.1365-2362.2011.02638.x. PMID22224829.
“eNOS haplotype associated with hypertension in obese children and adolescents”. International Journal of Obesity35 (3): 387–92. (Mar 2011). doi:10.1038/ijo.2010.146. PMID20661250.
“Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus”. Atherosclerosis189 (1): 241–6. (Nov 2006). doi:10.1016/j.atherosclerosis.2005.12.011. PMID16427644.
“Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy”. Journal of Hypertension24 (12): 2393–7. (Dec 2006). doi:10.1097/01.hjh.0000251899.47626.4f. PMID17082721.
“Endothelial nitric oxide synthase haplotypes associated with hypertension do not predispose to cardiac hypertrophy”. DNA and Cell Biology29 (4): 171–6. (Apr 2010). doi:10.1089/dna.2009.0955. PMID20070154.
“Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia”. Molecular Human Reproduction16 (7): 506–10. (Jul 2010). doi:10.1093/molehr/gaq030. PMID20457799.
“Endothelial nitric oxide synthase genotype and haplotype are not associated with diabetic retinopathy in diabetes type 2 patients”. Nitric Oxide15 (4): 417–22. (Dec 2006). doi:10.1016/j.niox.2006.02.002. PMID16581274.
“eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril”. European Journal of Clinical Pharmacology69 (2): 167–77. (Feb 2013). doi:10.1007/s00228-012-1326-2. PMID22706620.
“Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction”. The Pharmacogenomics Journal13 (2): 189–96. (Apr 2013). doi:10.1038/tpj.2011.49. PMID22064666.
“Pharmacogenetics of erectile dysfunction: navigating into uncharted waters”. Pharmacogenomics15 (11): 1519–38. (Aug 2014). doi:10.2217/pgs.14.110. PMID25303302.
